Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study

Intervention Clinical Trial

— XXS  

Official title:

Xpert Stent Versus Balloon Angioplasty in Complex Lesions of Small Arteries Below the Knee

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00546845
• Other study ID #: XXS
• Status: Recruiting
• Phase: Phase 4
• First received: October 17, 2007
• Last updated: August 4, 2011
• Start date: September 2007
• Est. completion date: June 2014

Study information

• Verified date: October 2007
• Source: University Hospital Tuebingen
• Contact: Gunnar Tepe, MD
• Phone: 49 7071 2983371
• Email: gunnar.tepe[@]med.uni-tuebingen.de
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is an investigator-initiated study. The study will be performed as a prospective, randomized, controlled multi-center trial to evaluate the safety and efficiency of Xpert stents compared to PTA in patients with chronic distal artery occlusions or stenosis undergoing catheter revascularization. Patients will be eligible for randomization if they are over 18 years old, if they undergo percutaneous catheter revascularization of an artery below the knee stenosis/occlusion that is less than 15 centimeters in length. Up to two vessels may be treated in this study. All lesions greater than 50% in the below the knee artery region have to be treated either with PTA or stenting according to the randomization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: June 2014
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Clinical:

1. Age between 18 and 95 years. 2. Subject or subject's legal representative have been informed of the nature of the study, and have signed the patient informed consent form. Patient is willing to take part in the follow-up protocol of the XXS study.

3. Rutherford stage 4 and 5 Anatomical:

1. Additional lesions inflow lesions might be successfully treated before randomization and treatment of the target lesion. The inflow lesions which were treated before randomization should only be classified TASC A or B. (TASC= Trans Atlantic Intersociety Conference)

2. Target vessel with documented run-off to the foot distally of the index lesion with patent plantar arteries

3. Reference vessel diameter of the target lesion should be = 2 and = 5 mm.

4. Maximum treated length in the target vessel is 15 cm (might also be divided up into multiple segments with up to 3 different lesions being treated).

5. Maximum of treated vessels per leg below the knee: 2 (all treated vessels should be treated within the randomization to the study group [PTA or stenting]).

6. Minimum distance target lesion to talus is 5 cm.

Exclusion Criteria:

• Clinical

1. Life expectancy due to a non-atheroslerotic disease less than 12 months.

2. Previous bypass surgery < 30 days prior to the study procedure.

3. Known allergies or sensitivities to heparin, contrast media, aspirin, clopidogrel, and nitinol which cannot be treated with antihistamines.

4. eGFR less than 29 mL/min/1.73m2 (K-DOQI Class 4 and 5) in patients which are not currently treated with dialysis (equivalent to a serum creatinine level of 2.4 mg/dL in a 70 year old male patient)

5. Subject with breast feeding plans, or child bearing potential with no birth control.

6. Subjects enrolled in another study concerning the index vessel(s) within 3 months prior to the study procedure.

7. Untreatable bleeding diatheses.

8. Patients who have an indication of being treated with coumadin after the intervention.

9. Inability to ambulate

10. Hypercoagulable state

11. Patients with age <18 years and patients who are not able to sign the informed consent form

Anatomical:

1. Inflow is obstructed and cannot be successfully treated prior to randomization and treatment of below the knee arteries.

2. Acute thrombus present in the target limb.

3. Previously implanted stent in the target vessel(s).

4. Aneurysms in the index leg.

5. Index vessel with no documented run-up to the foot (please also see inclusion criteria, anatomical).

6. Inability to use femoral access

7. No patent pedal arteries

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cronic Limb Ishemia
• Intervention

Intervention

Device:
• Balloon angioplasty
Balloon angioplasty. Only stent if PTA fails
• Use of self-expanding Expert stent
Nitinol stent

Locations

Country	Name	City	State
Germany	Universtiy of Tuebingen	Tuebingen	BW

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Tuebingen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MLD at the target lesion assessed by angiography	treatment effect dependent if stent of PTA was choosen	after 12 +/-2 months	Yes
Secondary	1. Interventional success rate. Interventional success is defined as restenosis less than 50%. 2. Late lumen loss (LLL)	treatment effect dependent on the PTA vs. Stent	after 1, 6, 12 months and 3 years	Yes
Secondary	3. Binary restenosis	Treament effect in long-term	arter 6, 12 months and 3 years	Yes
Secondary	4. Number of patients initially randomized to the PTA group, but receiving stents because of the suboptimal interventional success.	success rate of PTA only	intervention	Yes
Secondary	Target lesion revascularization, clinical stage, hospital days	treatment effect dependet if patients received stents or PTA only	after 1, 6, 12 months, and 3 years	Yes